O

Oncoinvent ASA
OSE:ONCIN

Watchlist Manager
Oncoinvent ASA
OSE:ONCIN
Watchlist
Price: 41.42 NOK 1.77%
Market Cap: kr186.6m

Net Margin

-1 990.4%
Current
Improving
by 41 837.8%
vs 3-y average of -43 828.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 990.4%
=
Net Income
kr-107.6m
/
Revenue
kr5.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 990.4%
=
Net Income
kr-107.6m
/
Revenue
kr5.4m

Peer Comparison

Country Company Market Cap Net
Margin
NO
Oncoinvent ASA
OSE:ONCIN
186.6m NOK
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
211.5B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
146B USD
Loading...

Market Distribution

Lower than 95% of companies in Norway
Percentile
5th
Based on 970 companies
5th percentile
-1 990.4%
Low
-4 257 300% — -4.2%
Typical Range
-4.2% — 6.7%
High
6.7% — 82 378.7%
Distribution Statistics
Norway
Min -4 257 300%
30th Percentile -4.2%
Median 0.8%
70th Percentile 6.7%
Max 82 378.7%

Oncoinvent ASA
Glance View

Market Cap
186.6m NOK
Industry
Pharmaceuticals

Oncoinvent ASA engages in the development of cancer treatment products. The company is headquartered in Oslo, Oslo and currently employs 34 full-time employees. The company went IPO on 2024-12-13. The firm is engaged in the development of alpha-emitting radiotherapeutics that provide better treatment options to cancer patients. The firm offers Radspherin, which is alpha-emitting radioactive microsphere therapy designed for the treatment of metastatic cancers in body cavities. The product candidate is a suspension of inorganic microspheres labelled with an alpha-emitting radioisotope for local administration. More specifically it consists of with calcium carbonate micro particles labelled with the radioisotope Radium-224d. The therapeutic goal is to treat residual micro metastases remaining after surgery in intracavitary surfaces and liquid without subjecting deeper regions of organs and tissues to harmful radiation doses.

ONCIN Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 990.4%
=
Net Income
kr-107.6m
/
Revenue
kr5.4m
What is Oncoinvent ASA's current Net Margin?

The current Net Margin for Oncoinvent ASA is -1 990.4%, which is above its 3-year median of -43 828.3%.

How has Net Margin changed over time?

Over the last 3 years, Oncoinvent ASA’s Net Margin has increased from -39 328.3% to -1 990.4%. During this period, it reached a low of -77 666.3% on Dec 31, 2022 and a high of -1 990.4% on Jun 30, 2025.

Back to Top